A high incidence of hepatocellular carcinoma has been reported in end-stage renal disease patients. This study was undertaken to evaluate whether this was caused by a high rate hepatitis or ouremia' per se.We used claims data of the Bureau of National Health Insurance of Taiwan for analysis. All patients diagnosed with end-stage renal disease having received their first dialysis between 1 January 2003 and 31 December 2007 (n 38 714) were enrolled for the study. A database of 1 million randomly selected subjects matched for age, gender, hepatitis B and C infection, and liver cirrhosis for the same period was used as control (n 38 714). The longest observation period was up to 31 December 2008.There was no significant difference in the incidence of hepatocellular carcinoma between end-stage renal disease patients and their non-end-stage renal disease counterparts (2.03 per 1000 person-years vs. 2.10 per 1000 person-years, rate ratio 0.947; 95 confidence interval: 0.7921.132). End-stage renal disease patients with hepatocellular carcinoma had higher percentages of diabetes mellitus, hypertension, heart failure and gout (all P 0.001), and they presented with a worse cumulative survival rate than the non-end-stage renal disease group (P 0.001). End-stage renal disease patients developing hepatocellular carcinoma were younger, and had more comorbidities than their non-end-stage renal disease counterparts. End-stage renal disease (hazard ratio 1.61) and diabetes mellitus (hazard ratio 1.55) were found to be independent factors for mortality in hepatocellular carcinoma patients.After matching for hepatitis and liver cirrhosis, end-stage renal disease is not associated with a higher incidence of hepatocellular carcinoma than the general population. The high incidence of hepatocellular carcinoma in end-stage renal disease patients was caused by a high viral hepatitis rate rather than ouremia' per se. Owing to increased comorbidity, end-stage renal disease patients developing hepatocellular carcinoma had worse long-term survival than non-end-stage renal disease patients.
關聯:
Japanese Journal of Clinical Oncology, 42(9), 780-786
